Histone variants:critical determinants in tumour heterogeneity

作     者：Tao Wang Florent Chuffart Ekaterina Bourova-Flin Jin Wang Jianqing Mi Sophie Rousseaux Saadi Khochbin 

作者机构：CNRS UMR 5309InsermU1209University of Grenoble AlpesInstitute for Advanced Biosciences38706GrenobleFrance State Key Laboratory for Medical Genomics and Department of HematologyShanghai Institute of HematologyCollaborative Innovation Center of Systems BiomedicinePole Sino-Francais des Sciences du Vivant et GenomiqueRuijin Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai 200025China 

出 版 物：《Frontiers of Medicine》 (医学前沿（英文版）)

年 卷 期：2019年第13卷第3期

页      面：289-297页

核心收录：

学科分类：10[医学] 

基　　金：prepared in frame of “Pitcher” research program on tumour heterogeneity supported by Cai Yuanpei program and by the “Pole Sino-Francais des Sciences du Vivant et Genomique.” supported by a grant from “Foundation pour la Recherche Medicale (FRM)”“analyse bio-informatique pour la recherche en biologie”program by ANR Episperm 3 program.Additional support is from: the “Universite Grenoble Alpes” SYMER programs Fondation ARC “Canc'air” project Plan Cancer 

主　　题：cancer-testis TH2B TH2A HIT H1.0 H1F0 linker histones 

摘      要：Malignant cell transformation could be considered as a series of cell reprogramming events driven by oncogenic transcription factors and upstream signalling *** plasticity and dynamics are critical determinants in the control of cell *** increase in chromatin dynamics could therefore constitute an essential step in driving oncogenesis and in generating tumour cell heterogeneity,which is indispensable for the selection of aggressive properties,including the ability of cells to disseminate and acquire resistance to *** supply and dosage,as well as histone variants,are the best-known regulators of chromatin *** facilitating cell reprogramming,histone under-dosage and histone variants should also be crucial in cell transformation and tumour *** we summarize and discuss our knowledge of the role of histone supply and histone variants in chromatin dynamics and their ability to enhance oncogenic cell reprogramming and tumour heterogeneity.